Case Report: PDF OnlyChronic Myeloid Leukemia After Treatment with 131I for Thyroid CarcinomaWang, Kang-Ling1; Lin, Liang-Yua; Chen, Po-Minb, c; Lin, Hong-Daa, c, *Author Information 1Division of Endocrinology and Metabolism, Armed Forces Tao-Yuan General Hospital, Taipei, Taiwan, R.O.C. aDivision of Endocrinology and Metabolism, Taipei, Taiwan, R.O.C. bDivision of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C. cNational Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C. *Correspondence to: Dr. Hong-Da Lin, Division of Endocrinology and Metabolism, Department of Internal Medicine, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan, R.O.C. E-mail: [email protected] Received: July 7, 2004 • Accepted: October 29, 2004 Journal of the Chinese Medical Association: May 2005 - Volume 68 - Issue 5 - p 230-233 doi: 10.1016/S1726-4901(09)70213-8 Metrics Abstract A 27-year-old male developed Philadelphia chromosome-positive chronic myeloid leukemia (CML) 13 years after a first dose of radioiodine (131I) therapy for papillary thyroid carcinoma. He had received a cumulative 131I dose of 670 mCi, in 8 divided doses over 8 years, up to April 1998, for ablation of 131I avid tissues over the anterior neck region. The leukemogenic potential of radioactive iodine has been pointed out by many authors, but most reported cases have been acute leukemias. A literature review disclosed only 9 cases similar to ours. At present, there is no evidence to prove whether the development of CML after thyroid carcinoma represents a treatment-induced complication, a coincidence, or an increased susceptibility to secondary malignancies due to the malignant process itself. © 2005 by Lippincott Williams & Wilkins, Inc.